There is growing evidence that metabolic
reprogramming plays an important role in cancer
development and progression [3]. Elevated fatty acid
synthesis is one of the most important alterations of
cancer cell metabolism. Previous studies have found
that many cancer cells show high rates of de novo lipid
synthesis, including pancreatic cancer [4], hepatocellular
carcinoma [5], breast cancer [6], and prostate cancer [7].
Accumulation of lipid droplets is a frequently observed
phenotype in cancer and is a manifestation of abnormal
lipid metabolism [8]. A recent study reveals that lipid
droplet, as a dynamic organelle, can not only provide
energy through β-oxidation for the tumor cells when
required, but also play an important role in signaling
transduction related with carcinogenesis and cancer cell
survival [9]. Inhibition of key enzymes and genes involved
in lipogenesis could obviously slow down the growth of
tumor cells and impairs their survival [10]. Therefore, to
find agents targeting lipogenesis may serve as a promising
strategy to treat cancer.